BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	42	86	602	569	1,126	263
Market Cap Growth	-84.07%	-85.65%	5.82%	-49.47%	327.27%	336.30%
Enterprise Value	70	122	502	337	914	232
PE Ratio	-	-0.48	-3.63	-5.32	-13.70	-7.99
PS Ratio	23.94	62.58	1605.17	-	-	-
PB Ratio	-1.19	-1.53	7.84	2.57	5.45	9.80
P/FCF Ratio	-0.72	-0.56	-4.44	-6.89	-16.89	-9.42
P/OCF Ratio	-0.72	-0.56	-4.45	-6.92	-16.97	-9.72
EV/Sales Ratio	39.79	88.53	1338.80	-	-	-
EV/EBITDA Ratio	-0.82	-0.74	-3.19	-3.16	-11.15	-7.08
EV/EBIT Ratio	-0.82	-0.74	-3.19	-3.15	-11.13	-7.04
EV/FCF Ratio	-0.95	-0.79	-3.71	-4.08	-13.71	-8.30
Debt / Equity Ratio	-1.41	-1.79	1.22	0.00	0.01	0.04
Debt / EBITDA Ratio	-0.73	-0.61	-0.60	-0.01	-0.02	-0.03
Debt / FCF Ratio	-0.85	-0.65	-0.69	-0.01	-0.02	-0.04
Quick Ratio	2.37	2.39	5.90	13.98	18.00	3.83
Current Ratio	2.57	2.65	6.17	14.21	18.33	4.03
Asset Turnover	0.02	0.01	0.00	0	0	0
Interest Coverage	-10.29	-12.45	-19.18	-2672.27	-3042.30	-1647.40
Return on Equity (ROE)	374.20%	1872.60%	-118.00%	-46.40%	-59.40%	-111.00%
Return on Assets (ROA)	-154.40%	-144.90%	-72.90%	-43.50%	-53.40%	-85.20%
Return on Capital (ROIC)	-488.69%	-385.77%	-93.57%	-48.00%	-39.55%	-120.33%
Earnings Yield	-364.10%	-207.35%	-27.54%	-18.80%	-7.30%	-12.51%
FCF Yield	-286.38%	-179.52%	-22.51%	-14.52%	-5.92%	-10.62%
Buyback Yield / Dilution	-7.87%	-3.98%	-6.23%	-21.63%	-33.11%	-11.79%
Total Shareholder Return	-7.87%	-3.98%	-6.23%	-21.63%	-33.11%	-11.79%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).